anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a health care product for delaying cognitive dysfunction of diabetes, which comprises the following components: ginseng extract, astragalus extract, polygonum multiflorum extract, medlar extract, hordei yumai beard extract and leech extract. The cognitive dysfunction of diabetes belongs to the category of dementia in traditional Chinese medicine. The brain is deficient due to the loss of the marrow and the loss of the mental function. It is manifested as mental retardation, slow response, amnesia, etc. For treatment, the method of tonifying kidney, nourishing marrow and replenishing essence is used. In the invention, ginseng and astragalus root are the essential drugs for tonifying qi, prepared fleece-flower root and wolfberry fruit are the good products for tonifying kidney, jade wheat beard is the good product for regulating lipid and reducing blood sugar, leech is the essential drug for activating blood, the six drugs are used together for replenishing essence and benefiting marrow, the activities of SOD and catalase are improved, and Lipid Peroxide (LPO) and lipofuscin are reduced, thereby improving the learning ability, relieving the memory decline, improving the learning and memory disorders and finally achieving the purpose of improving the cognitive dysfunction symptoms of diabetes.
Prospective investigator-blinded study involving 13 adult male and female subjects with vitiligo on the backs of both hands. Punch minigrafting will be performed on both hands taking skin from the thighs and/or buttocks. Light treatments will be administered starting at week one after grafting. One hand will receive narrow-band ultraviolet B light and the other will receive focal 308-nm light treatments. Light treatments will be administered 3 times per week for 12 weeks. A long term follow-up visit will be completed at week 25. The investigator will evaluate the subjects at week 4, 7, 13 and 25 in addition to screening and baseline evaluations/procedures.
Described herein is an aerosol hairspray product comprising a container wall enclosing a reservoir. The reservoir contains from about 40% to about 70% of a hairstyling formulation and from about 30% to about 60% of a dimethyl ether propellant. The hairstyling formulation comprises water, one or more hairstyling polymers, and from about 0.05% to about 2% alcohol. A spray device is attached to the container. The spray device includes a valve having a valve housing including an aerosol tap area. A dip tube is connected to the valve. The dip pipe comprises a dip pipe hole with a certain dip pipe hole area. The ratio of the aerosol tap area to the dip tube aperture area is from about 0.005 to about 0.15.
Individuals with homozygous beta thalassemia are either severely anemic or dependent on blood transfusion to sustain life. Deficient synthesis of the beta chain leads to imbalanced chain synthesis with an excess of alpha globin. This alpha globin precipitates, causing ineffective erythropoiesis and shortened red cell survival. Hydroxyurea is a cell-cycle specific agent that blocks DNA synthesis by inhibiting ribonuclease reductase, the enzyme that converts ribonucleotides to deoxyribonucleotides. Administration of hydroxyurea to primates and more than 300 patients with sickle cell anemia has been frequently, but not invariably associated with a substantial increase in synthesis of gamma globin. In patients with homozygous beta-thalassemia, enhanced gamma globin synthesis could partially compensate for the deficient synthesis of beta globin rendering chain synthesis more balanced and reducing the relative excess of alpha chains. The purpose of this protocol is to test the hypothesis that chronic daily low dose administration of hydroxyurea will enhance gamma globin synthesis, increase red cell production and partially or substantially correct the anemia in patients with homozygous beta-thalassemia. The effect of treatment will be monitored by serial determination of the hemoglobin and hematocrit. The relationship between response to therapy and the specific beta-globin mutation(s) will also be analyzed. This study will therefore examine a cohort of patients not previously treated with hydroxyurea.
Xeroform® Petrolatum Dressing (Xeroform® / Control Dressing) is fine mesh gauze impregnated with 3% Bismuth Tribromophenate in a special petrolatum blend. The dressing is a non adherent dressing that clings and conforms to all body parts.
The present invention relates to the biotechnology field, more particularly, to novel recombinant staphylokinase (RGD/KGD-Sak) derivatives and the preparation the thereof. The derivatives, have a low polymerizing ability, low immunogenicity and a bifunctionality of thrombolytics and anticoagulant. Based on the line, structural analysis of the monomer and dimer of recombinant staphylokinases and their biochemical properties, we designed two novel bifunctional staphylokinase molecular structures. Mutant genes were constructed by PCR site-directed mutagenesis which were then recombined with a prokaryotic vector and used to transform  E. coli . Engineered strains with a high expression level were selected by screening and propagated by fermentation, followed by disruption of the cells, centrifugation to collect inclusion bodies, renaturation, and purification of RGD/KGD-SAK through a two-step method. After lyophilized, the polymerizing ability and immunogenicity of the products decreased significantly. The derivatives can not only activate fibrinogen to lyse thrombus, but also significantly inhibit the platelet aggregation induced by ADP, suggesting that they have the bifunctionality of thrombolytics and anticoagulant.
FIELD: medicine. ^ SUBSTANCE: invention includes obtaining and applying the versions of allergens of 5 Pooideae group, which are characterised by decreased IgE reactivity in comparison to known wild-type allergens and at the same time by essentially retained reactivity in comparison to T-lymphocytes. Versions of allergens, as per the invention, do not have at least one section or a combination of sections corresponding to amino-acid sequence of sections Phl p5a 94-113 or 175-198, which is given in the description. Versions of allergens have been obtained by gene-engineering methods. In the invention is opened DNA molecule encoding the version of allergen, recombinant expression vector, host organism, expression version of allergen and method of obtaining the version of allergen by using the above described means. Such hypoallergic versions of allergens can be used as a remedy against allergies determined by allergens of 5 Pooideae group for specific immunotherapy (hyposensitisation) of the patients having grass pollen allergy or for preventive immunotherapy of grass pollen allergies by using pharmaceutical composition. ^ EFFECT: preparations based on versions of allergens, as per the invention, have decreased IgE reactivity and the retained reactivity in relation to T-lymphocytes. ^ 12 cl, 17 dwg, 3 tbl
AIMS: The conditions of hypoxia are suggested to induce permanent atrial fibrillation (AF). The regulation of COX4I2 and COX4I1 depends on oxygen availability in tissues. A role of COX4I2 in the myocardium of AF patients is supposed for pathogenesis of AF and subsequent alterations in the electron transfer chain (ETC) under hypoxia.
METHODS AND RESULTS: In vitro, influence of hypoxia on HeLa 53 cells was studied and elevated parts of COX 4I2 were confirmed. Myocardial biopsies were taken ex vivo from the patients' Right Atria with SR (n = 31) and AF (n = 11), respectively. RT- PCR for mRNA expresson, mitochondrial respiration by polarography and the protein content of cytochrome c oxidase (CytOx) subunit 4I1 and CytOx subunit 4I2 by ELISA were studied. Clinical data were correlated to the findings of gene expressions in parallel. Patients with permanent AF had a change in isoform 4I2/4I1 expression along with a decrease of isoform COX 4I1 expression. The 4I2/4I1 ratio of mRNA expression was increased from 0.630 to 1.058 in comparison. However, the protein content of CytOx subunit 4 was much lower in the AF group, whereas the respiration/units enzyme activity in both groups remained the same.
CONCLUSIONS: This study describes a possible molecular correlate for the development of AF. Due to the known functional significance of COX 4I2, mitochondrial dysfunction can be assumed as a part of the pathogenesis of AF.
If the patient has to discontinue the study drug within the (stage 1) 6 month study period or during the subsequent follow-up period (up to month 12) because of a lack of response (or failure), flare or side effect, he/she will be randomized again to receive one of the remaining two study drugs (stage 2, with a 1:1 randomization ratio, colchicine 0.6 mg x 2/day; dapsone 150 mg/day; azathioprine 2 mg/kg/day) for 6 months. Endpoint in this second stage will again be the response to treatment at 6 months.
Participants of Japanese descent will be enrolled in 3 cohorts and will receive one of the corresponding SADs of JNJ-64417184 or placebo in a fasted state. Dosing may be changed from fasted to a fed state, depending on emerging PK data from Part 2A. The starting dose and formulation will be selected based on the outcome of Parts 1 and 2. Dose escalation in the subsequent cohorts will depend on the observed human Cmax and AUC in previous cohorts.
Subjects have had DDH in childhood. DDH has been diagnosed before age of 1,5 years and treated for.
Functional hypothalamic amenorrhea (FHA) is characterized by estrogen deficiency that significantly impacts metabolic, bone, cardiovascular, mental, and reproductive health. Given the importance of environmental factors such as stress and body composition, and particularly considering the importance of estrogens in regulating the gut microbiota, some changes in the intestinal microenvironment are expected when all of these factors occur simultaneously. We aimed to assess whether the gut microbiota composition is altered in FHA and to determine the potential impact of hormonal replacement therapy (HRT) on the gut microbiota. This prospective observational study included 33 patients aged 18-34 yr with FHA and 10 age-matched healthy control women. Clinical, hormonal, and metabolic evaluations were performed at baseline for the FHA group only, whereas gut microbiota profile was assessed by 16S rRNA gene amplicon sequencing for both groups. All measurements were repeated in patients with FHA after receiving HRT for 6 mo. Gut microbiota alpha diversity at baseline was significantly different between patients with FHA and healthy controls (P < 0.01). At the phylum level, the relative abundance of Fusobacteria was higher in patients with FHA after HRT (P < 0.01), as was that of Ruminococcus and Eubacterium at the genus level (P < 0.05), which correlated with a decrease in circulating proinflammatory cytokines. FHA is a multidimensional disorder that is interconnected with dysbiosis through various mechanisms, particularly involving the gut-brain axis. HRT appears to induce a favorable shift in the gut microbiota in patients with FHA, which is also associated with a reduction in the systemic inflammatory status.NEW & NOTEWORTHY Our study marks the first comprehensive analysis of gut microbiota composition in FHA and the impact of HRT on it, along with biochemical, anthropometric, and psychometric aspects. Our results indicate distinct gut microbiota composition in patients with FHA compared with healthy individuals. Importantly, HRT prompts a transition toward a more beneficial gut microbiota profile and reduced inflammation. This study validates the concept of FHA as a multifaceted disorder interlinked with dysbiosis, particularly involving the gut-brain axis.
Method for preparing botulinum neurotoxin and nanoparticle thereof are provided. The method includes fermenting bacteria  Clostridium botulinum  in a fermentation media free of animal-derived ingredients and contacting the fermentation media with an anion exchange media slurry and obtaining a supernatant including the botulinum neurotoxin by centrifugation. The method further includes dialyzing the supernatant and collecting a dialyzed solution including the botulinum neurotoxin, contacting the dialyzed solution with an anion exchange chromatography column, contacting an elute collected from the anion exchange chromatography column with a cation exchange chromatography column, and collecting an elute. The nanoparticle includes multi-layer including an innermost water phase core including biomolecules encapsulated by an oil phase layer, thereby forming a water-in-oil structure, water phase layers; oil phase layers; and an outmost cream layer. The water phase layers and the oil phase layers alternatively encapsulate the water-in-oil structure. The biomolecules include botulinum neurotoxin and/or hyaluronic acid.
Telerehabilitation program will be applied 5 days a week for 3 weeks to patients in the telerehabilitation group. A physiatrist will meet with patients via videoconferencing over the internet and guide the program.
Octagam 5% liquid is contraindicated in patients who have acute severe hypersensitivity reactions to human immunoglobulin.

Octagam 5% liquid contains trace amounts of IgA (not more than 0.2 mg/ml in a 5% solution). It is contraindicated in IgA deficient patients with antibodies against IgA and history of hypersensitivity (See Description [11]).

Octagam 5% liquid is contraindicated in patients with acute hypersensitivity reaction to corn. Octagam 5% liquid contains maltose, a disaccharide sugar which is derived from corn. Patients known to have corn allergies should avoid using Octagam 5% liquid.
LED applications at the beginning, with a dose of 8 J/cm2, will be performed shortly after the blood collections, with a maximum period of 10 minutes, in which the participants of the other groups should remain in rest passive. At the end of these 10 minutes, a 5 minute warm up will be performed and then the tests will be started.
AIM: Here we present the patients whose body mass index is in the normal range and who visited with the complaint of headache. The differences in lipid profile in this group compared to healthy children and the risk factors that may be associated with this were investigated.
MATERIALS AND METHODS: 195 patients who applied to the Pediatric Neurology outpatient clinic with headache complaints between April 2021 and October 2022 were retrospectively examined. 201 healthy children were included as the control group. The gender, age, headache type, lipid profile blood test after at least 8 h of fasting [total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride (TG), and TG/HDL ratio], and body mass index (BMI) were recorded. Those patients who had a BMI range of 18.5-24.9 kg/m2 were included in the study.
RESULTS: The study group had 195 patients; 118 girls (60.5%). The average age was 12,57 ± 3,48 years, and 114 patients (58.5%) had tension-type headaches and 81 (41.5%) had migraine-type headaches. There was no significant difference in age and gender between the two groups. Blood pressure, folate, and thyroid function tests were normal. In the lipid profile, a significant difference was observed between total cholesterol, LDL, HDL, and TG in the study group compared to the control group (p < 0.05). However, there was no difference in the TG/HDL ratio between those two groups. No significant statistical difference was observed in the lipid profile and other laboratory findings between headache types.
CONCLUSION: In children presenting with headache complaints, which can be both worrying for families and cause significant loss of functionality, it is detectable (obviously) that headache is an important marker for dyslipidemia; even if BMI is in a normal range. The lipid profile should be seen both to control the complaint with an appropriate diet and to observe the risk of future atherosclerotic processes.
Therapeutic agents comprising plural therapeutic compounds self assembled into high axial ratio microstructures are described. The threapeutic compounds satisfy the formula HARFM-Th, wherein HARFM is a high axial ratio forming material and Th is a therapeutic associated with the HARFM. The therapeutic agent also can satisfy the formula HARFM-S-Th, wherein S is a spacer. Release of the therapeutic by the agent generally follows either 0-order kinetics or psuedofirst order kinetics. A method for delivering drugs to animals or persons also is described. The method comprises administering an effective amount of a therapeutic self-assembled into an HAR microstructure to the animal or person.
PROBLEM TO BE SOLVED: To provide a cosmetic composition containing such gels as to obtain efficient optical blurring of wrinkles, fine lines, pores, skin imperfections, and the like.SOLUTION: The invention relates to a non-aqueous cosmetic composition containing gel 10, which is present in an amount of 1-100% to the weight of the cosmetic composition. The Gel 10 contains (a) a fractal network 30 of a nanoparticle 20, and (b) a translucent macro particle 15 covered with the fractal network 30 of the nanoparticle 20. The refractive index of the nanoparticle 20 is not consistent with the refractive index of the macro particle 15. The cosmetic composition contains less than 1% of water. The gel 10 is a non-aqueous dispersing element of a first nanoparticle 20 and a second nanoparticle 20. The gel 10 has a pH so that the first and second nanoparticles 20 have surface charge of a positive or negative reversal sign. The first and second nanoparticles 20 have a particle diameter in a range of 50-900 nanometers. The refractive index is in a range of 1.38-2. The macro particle 15 has a particle diameter of 2-50 micrometers.SELECTED DRAWING: Figure 1
The present inventiondiscloses a sports training system and method based on VR technology, which includes a human body data collection module, data preprocessing module, data processing module, and data storage module. The method comprises the steps: Step 1, data collection; Step 2, training guidance; Step 3, training result feedback; Step 4, training plan formulation; Step 5, training plan optimization. Compared to existing real-world sports training, this invention leverages VR technology for simulated teaching and training, which can enhance the efficiency of sports training while reducing time and equipment costs. The invention is capable of providing real- time feedback on training results and human body data, aiding trainees in improving their movements and boosting the effectiveness of training. Furthermore, this invention can formulate training plans based on collected human body data and update and optimize these plans based on training results, enabling personalized teaching. This approach helps prevent physical injuries due to excessive training intensity and avoids failing to meet training goals due to insufficient intensity.
In a method and system for providing clinical knowledge from a provider to a medical user based on one or more diagnostic questions submitted by the user to the provider, a clinical knowledge communication server is provided with an associated knowledge database. The at least one or more diagnostic questions are sent by the user to the server. With the server, an initial examination of the at least one or more diagnostic questions is conducted. Examination steps are associated with the at least one or more diagnostic questions and placed in a sequence. The sequence of examination steps are then sent to the medical user. The provider may also request clinical knowledge from the medical user such as, for example, relating to the diagnostic questions submitted by the user.
The intervention will be delivered via synchronous videoconferencing (real-time delivery and communication between the navigator and the participant) by a trained patient navigator and will consist of 5, 30-minute sessions delivered every week. The navigation intervention group will also receive an online or mailed copy of the health insurance resource guide.
Ischemia-reperfusion (IR) induces a wide range of irreversible injuries. Cerebral IR injury (IRI) refers to additional brain tissue damage that occurs after blood flow is restored following cerebral ischemia. Currently, no established methods exist for treating IRI. Oxidative stress is recognized as a primary mechanism initiating IRI and a crucial focal target for its treatment. Urolithin B, a metabolite derived from ellagitannins, antioxidant polyphenols, has demonstrated protective effects against oxidative stress in various disease conditions. However, the precise mechanism underlying UB's effect on IRI remains unclear. In our current investigation, we assessed UB's ability to mitigate neurological functional impairment induced by IR using a neurological deficit score. Additionally, we examined cerebral infarction following UB administration through TTC staining and neuron Nissl staining. UB's inhibition of neuronal apoptosis was demonstrated through the TUNEL assay and Caspase-3 measurement. Additionally, we examined UB's effect on oxidative stress levels by analyzing malondialdehyde (MDA) concentration, superoxide dismutase (SOD) activity, and immunohistochemistry analysis of inducible nitric oxide synthase (iNOS) and 8-hydroxyl-2'-deoxyguanosine (8-OHdG). Notably, UB demonstrated a reduction in oxidative stress levels. Mechanistically, UB was found to stimulate the Nrf2/HO-1 signaling pathway, as evidenced by the significant reduction in UB's neuroprotective effects upon administration of ATRA, an Nrf2 inhibitor. In summary, UB effectively inhibits oxidative stress induced by IR through the activation of the Nrf2/HO-1 signaling pathway. These findings suggest that UB holds promise as a therapeutic agent for the treatment of IRI.
Topical aqueous liquid compositions for application to the epidermis which provide a germicidal benefit thereto comprising: 0.02-10% wt. of a germicidally effective amount of a quaternary ammonium surfactant compound, 0.1-25% wt. of at least one anionic surfactant constituent which excludes anionic surfactants of the sulfate and sulfonate types, 0.1-15% wt. of a cationic conditioner constituent, 0-10% wt. of a foam stabilizer constituent; at least 70% wt. of water, and optionally one or more of optional constituents which may be used to impart an aesthetic benefit, e.g., color, fragrance, or a further technical benefit, e.g., viscosity adjustment, to the liquid compositions, characterized in that: (a) the weight ratio of the germicidally effective quaternary ammonium and cationic conditioner constituent to the anionic surfactant constituent is not less than 0.6; and/or, (b) the weight ratio of the germicidally effective quaternary ammonium surfactant compound to the cationic conditioner constituent is less than 0.14; and/or, (c) the ratio of the cationic conditioner constituent to the anionic surfactant constituent is at least 0.5; and, (d) the pH of the liquid composition is between about 3.5 and about 7.5.